Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.53 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CPN1 | P15169 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7319347 | 1.00 | CYP2C19 (0.57) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| SCHEMBL7319341 | 1.00 | CYP2C19 (0.57) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| Hydrochloric Acid SCHEMBL7609245 | 0.98 | CYP2C19 (0.55) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| SCHEMBL28332935 | 0.91 | CPN1 (0.48) | CYP2C19GABBR2GABBR1EPHX1CYP2D6 | |
| SCHEMBL27543440 | 0.89 | PTGS2 (0.55) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| SCHEMBL1310192 | 0.88 | CHRNB2 (0.57) | CYP2C19GABBR2GABBR1 | |
| SCHEMBL27582649 | 0.86 | GABBR2 (0.53) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| SCHEMBL637030 | 0.84 | EPHX1 (0.66) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| SCHEMBL12323888 | 0.84 | EPHX1 (0.66) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| SCHEMBL11136320 | 0.83 | CYP2C19 (0.40) | CYP2C19GABBR2GABBR1EPHX1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 467 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023137366-A2 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | UNIVERSITY OF WASHINGTON (US) | 2023-07-20 | — | — | WO | claimed |
| US-20220077099-A1 | COMPOSITION FOR CONDUCTIVE ADHESIVE, SEMICONDUCTOR PACKAGE COMPRISING CURED PRODUCT THEREOF, AND METHOD OF MANUFACTURING SEMICONDUCTOR PACKAGE USING THE SAME | ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE (KR) | 2022-03-10 | — | — | US | claimed |
| CN-113956270-A | Preparation method of main degradation product of ceforanide | 成都大学 | 2022-01-21 | — | — | CN | claimed |
| US-20210154312-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2021-05-27 | — | — | US | claimed |
| US-10912840-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2021-02-09 | — | — | US | claimed |
| US-20180256737-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2018-09-13 | — | — | US | claimed |
| CN-108042811-A | For treating the conjugate of the disease as caused by PSMA expression cells | 恩多塞特公司 | 2018-05-18 | — | — | CN | claimed |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2016-12-15 | — | — | US | claimed |
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (IN) | 2016-12-15 | — | — | US | claimed |
| US-20150297735-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2015-10-22 | — | — | US | claimed |
| WO-2009117095-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | WO | claimed |
| WO-2009067639-A2 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BIOMARIN PHARMACEUTICAL INC. (US) | 2009-05-28 | — | — | WO | claimed |
| CN-101380317-A | Pharmaceutical composition for relieving pruritus | CAYMAN ISLAND SHANGANSHENG DEV (CN) | 2009-03-11 | — | — | CN | claimed |
| US-20090062521-A1 | AMIDITE FOR SYNTHESIZING MODIFIED NUCLEIC ACID AND METHOD FOR SYNTHESIZING MODIFIED NUCLEIC ACID | FUJITSU LIMITED (JP) | 2009-03-05 | — | — | US | claimed |
| US-20080193984-A1 | Process For Producing Amino Acid Derivative From Hydroxyimino Acid | AJINOMOTO CO., INC. (JP) | 2008-08-14 | — | — | US | claimed |
| EP-1316542-A1 | 3-AMINO-1-INDANOLE, METHOD OF SYNTHESIZING THE SAME AND METHOD OF OPTICAL RESOLUTION | Daicel Chemical Industries, Ltd. (JP) | 2003-06-04 | — | — | EP | claimed |
| US-20020177736-A1 | 3-AMINO-1-INDANOLE, METHOD OF SYNTHESIZING THE SAME AND METHOD OF OPTICAL RESOLUTION | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-28 | — | — | US | claimed |
| US-6479702-B1 | 3-amino-1-indanole, method of synthesizing the same and method of optical resolution | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-12 | — | — | US | claimed |
| US-5656448-A | Dipstick immunoassay device | PRINCETON BIOMEDITECH CORPORATION (US) | 1997-08-12 | — | — | US | claimed |
| CN-1088908-A | The chemical process of preparation 2-(2-aminomethyl phenyl)-3-methoxy-methyl acrylate | ZENECA LTD (GB) | 1994-07-06 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154312-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | CYP2C19 4553/4885GABBR2 4421/4885GABBR1 4571/4885 |
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | CYP2C19 4553/4885GABBR2 4421/4885GABBR1 4571/4885 |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | CYP2C19 4553/4885GABBR2 4421/4885GABBR1 4571/4885 |
| US-20020177736-A1 | 3-AMINO-1-INDANOLE, METHOD OF SYNTHESIZING THE SAME AND METHOD OF OPTICAL RESOLUTION | CYP51A1, IDO1, CYP8B1 | CYP2C19 238/4885GABBR2 1160/4885GABBR1 1168/4885 |
| US-10912840-B2 | Conjugates for treating diseases caused by PSMA expressing cells | FOLH1, KLK3, CD47 | CYP2C19 4553/4885GABBR2 4421/4885GABBR1 4571/4885 |
| US-20090062521-A1 | AMIDITE FOR SYNTHESIZING MODIFIED NUCLEIC ACID AND METHOD FOR SYNTHESIZING MODIFIED NUCLEIC ACID | NSUN2, RNMT, ADAR | CYP2C19 2244/4885GABBR2 4226/4885GABBR1 4676/4885 |
| US-20150297735-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | CYP2C19 4553/4885GABBR2 4421/4885GABBR1 4571/4885 |
| US-20180256737-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | CYP2C19 4553/4885GABBR2 4421/4885GABBR1 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.